(Q38028855)

27 August 2017

title

Anticoagulants in atrial fibrillation patients with chronic kidney disease (English)

1 reference

27 August 2017

0 references

1 reference

1 reference

John W Eikelboom

2

0 references

author name string

Robert G Hart

series ordinal

1

1 reference

27 August 2017

Alistair J Ingram

series ordinal

3

1 reference

27 August 2017

Charles A Herzog

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

24 July 2012

1 reference

Nature Reviews Nephrology

27 August 2017

published in

1 reference

27 August 2017

volume

8

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

569-578

1 reference

Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Apixaban in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Warfarin for atrial fibrillation in community-based practise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Kidney function influences warfarin responsiveness and hemorrhagic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Warfarin in atrial fibrillation patients with moderate chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Validation of Clinical Classification Schemes for Predicting Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Independent predictors of stroke in patients with atrial fibrillation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Risk of major hemorrhage for outpatients treated with warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Major bleeding in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Vascular calcification in chronic kidney disease: the role of vitamin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Warfarin in haemodialysis patients with atrial fibrillation: what benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

A new equation to estimate glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

21 January 2018

Chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Assessing kidney function--measured and estimated glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Development of a Contemporary Bleeding Risk Model for Elderly Warfarin Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Bleeding Risk with Dabigatran in the Frail Elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Atrial fibrillation in haemodialysis patients: do the guidelines for anticoagulation apply?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

Outcome of atrial fibrillation among patients with end-stage renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.160

K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients

31 March 2020

1 reference

12 December 2020

Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States

1 reference

12 December 2020

Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease

1 reference

12 December 2020

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation

1 reference

12 December 2020

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2012.160

1 reference

27 August 2017

1 reference